Posts Tagged ‘ dry eye ’
Denali Concrete Management Inc. Announces The Commencement Of Patient Enrollment For The Phase 3 Dry Eye Syndrome Study
Denali Concrete Management Inc. (OTCBB: DCMG) announced that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. This multi-center clinical trial is conducted in the United States, Europe and Israel...
Status of Strategic Partnership Discussions Related to RGN-259 Ophthalmic Eye Drop
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) is updating stockholders on the status of strategic discussions related to its ophthalmic drug candidate, RGN-259. Since data related to its Phase 2 dry eye clinical trial was released in November showing that RGN-259 had statistically significant benefits over placebo in certain signs and symptoms of dry eye syndrome, the company has been directly engaged in licensing.
New Dry Eye Treatments in the Pipeline
OSN: Several promising treatments are in the pipeline for dry eye, which is an “epidemic” and can drive patients to drink. Secretagogues stimulate the eye to produce its own tears, like Restasis. One is called Lancovutide which was originally used in cystic fibrosis. Rebamipide’s mechanism is to increase the mucin level in tears, which makes the tears more stable and less prone to evaporate. A company called Mimetogen is promoting a nerve growth (Read more...)
Don’t Use the Term “Dry Eye”- Use Dysfunctional Tear Syndrome
“Dry eye” is a misnomer. It confuses patients- how can their eyes be dry, when the most common symptom is tearing?!
Mimetogen Pharmaceuticals Announces Initiation Of Phase II Clinical Trial Of Novel NGF Mimetic In Patients With Dry Eye
Mimetogen Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing novel small molecule compounds that mimic the effects of neurotrophins, today announced that it has initiated the first human clinical trial evaluating MIM-D...
Celtic Therapeutics And Resolvyx Pharmaceuticals Announce An Alliance In Ophthalmology
Celtic Therapeutics Holdings L.P. (Celtic Therapeutics), a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions...
Subscribe
